Literature DB >> 10733666

Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.

H J Blaheta1, U Ellwanger, B Schittek, K Sotlar, E MacZey, H Breuninger, M H Thelen, B Bueltmann, G Rassner, C Garbe.   

Abstract

Histopathologic parameters of the primary tumor, such as Breslow's tumor thickness and Clark's level of invasion are the current basis for prognostic classifications of primary cutaneous melanoma. Once patients develop regional node metastasis, histopathologic features of the primary melanoma no longer contribute significantly to survival prediction. In this tumor stage, the extent of lymph node involvement is the main prognostic factor. This study addresses the question whether application of a highly sensitive molecular biology assay for detection of submicroscopic melanoma cells in sentinel lymph nodes may be suitable to improve melanoma staging. One hundred and sixteen patients with primary cutaneous melanoma with a total of 214 sentinel lymph nodes were enrolled. Sentinel lymph nodes were analyzed by histopathology including immunohistochemistry and by reverse transcription-polymerase chain reaction for tyrosinase. Patients were examined for tumor recurrences during a follow-up period of 19 mo (median). Disease-free survival probabilities were calculated and independent prognostic factors were determined by multivariate analysis. Using histopathology, micrometastatic nodal involvement was detected in 15 patients (13%). Of the 101 patients with histopathologically negative sentinel lymph nodes, 36 were reclassified by positive tyrosinase reverse transcription-polymerase chain reaction and 65 patients were still negative by reverse transcription-polymerase chain reaction. Recurrences were observed in 23 (20%) of 116 patients. These tumor recurrences were demonstrated in 10 patients (67%) with histopathologically positive sentinel lymph nodes, in nine patients (25%) with submicroscopic tumor cells detected by reverse transcription-polymerase chain reaction, and in four patients (6%) negative by both methods. The differences in recurrence rates were statistically significant (p = 0.01). In a multivariate analysis, histopathologic and reverse transcription-polymerase chain reaction status of the sentinel lymph node were demonstrated to be the only significant prognostic factors for predicting disease-free survival. Tyrosinase reverse transcription-polymerase chain reaction for the detection of minimal residual melanoma in sentinel lymph nodes is a powerful tool to determine patients who are at increased risk for subsequent metastasis. Moreover, a group of patients with high tumor thickness was identified by negative reverse transcription-polymerase chain reaction to be at low risk for recurrent disease. These data may have an impact on future tumor classifications of primary cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733666     DOI: 10.1046/j.1523-1747.2000.00925.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

1.  Quantification of melanoma mRNA markers in sentinel nodes: pre-clinical evaluation of a single-step real-time reverse transcriptase-polymerase chain reaction assay.

Authors:  Helene N Abrahamsen; Ebba Nexo; Torben Steiniche; Stephen J Hamilton-Dutoit; Boe S Sorensen
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

Review 2.  [Sentinel node biopsy. What are the facts?].

Authors:  M Möhrle; H Breuninger
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

Review 3.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

4.  The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.

Authors:  D Sahni; A Robson; G Orchard; R Szydlo; A V Evans; R Russell-Jones
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up.

Authors:  Thomas Kurt Eigentler; Joachim Hinderer; Seema Noor; Claus Garbe; Ulrike Leiter
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-19       Impact factor: 4.553

6.  "Stealth" melanoma cells in histology-negative sentinel lymph nodes.

Authors:  Eijun Itakura; Rong-Rong Huang; Duan-Ren Wen; Alistair J Cochran
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

7.  [Sentinel lymph node in melanoma].

Authors:  T Meyer; M Möhrle; C Garbe; W Hohenberger
Journal:  Chirurg       Date:  2004-08       Impact factor: 0.955

Review 8.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

9.  Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate.

Authors:  V Davids; S H Kidson; G S Hanekom
Journal:  Mol Pathol       Date:  2003-02

10.  Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of mice.

Authors:  Paula J Foster; Elizabeth A Dunn; Kristina E Karl; Jonatan A Snir; Colleen M Nycz; Alfred J Harvey; Ron J Pettis
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.